

Supplementary Table.S6 Multivariate analysis of impact factors on adjuvant chemotherapy and radiotherapy.

Adjuvant chemotherapy*				
Factor		OR	95%CI	P-value
Molecular subtypes	HER2+ vs Luminal (HER2-)	0.96	0.71-1.29	0.774
	TNBC vs Luminal (HER2-)	2.00	1.46-2.74	<0.001
NAT cycles	> 6 vs 4-6	0.30	0.23-0.39	<0.001
Adjuvant radiotherapy#				
Factor		OR	95%CI	P-value
Clinical stages	cT1-2N1 vs cT1-2N0	2.10	1.58-2.79	<0.001
	LABC vs cT1-2N0	3.73	2.70-5.17	<0.001

*Adjusted by neoadjuvant chemotherapy, neoadjuvant targeted therapy, axillary surgery, breast pCR status, ypN0 status (P value < 0.05 in the univariate analysis).

Adjusted by age, histology, neoadjuvant chemotherapy, NAT cycles, breast surgery, axillary surgery, ypN0 status (P value < 0.05 in the univariate analysis).

Abbreviations: HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; NAT, neoadjuvant therapy.